首页 | 本学科首页   官方微博 | 高级检索  
检索        

二陈汤加味对慢性阻塞性肺病大鼠细支气管IL-19,IL-20R1,IL-20R2表达的影响
引用本文:徐莉莉,尚立芝,王博宇,杨帆,杜宜航,张迪,黄萍萍,丰雪,张东洁,冯意会,谢文英.二陈汤加味对慢性阻塞性肺病大鼠细支气管IL-19,IL-20R1,IL-20R2表达的影响[J].中国实验方剂学杂志,2019,25(23):41-47.
作者姓名:徐莉莉  尚立芝  王博宇  杨帆  杜宜航  张迪  黄萍萍  丰雪  张东洁  冯意会  谢文英
作者单位:河南中医药大学, 郑州 450046,河南中医药大学, 郑州 450046,河南中医药大学, 郑州 450046,河南中医药大学, 郑州 450046,河南中医药大学, 郑州 450046,河南中医药大学, 郑州 450046,河南中医药大学, 郑州 450046,河南中医药大学, 郑州 450046,河南中医药大学, 郑州 450046,河南中医药大学, 郑州 450046,河南中医药大学, 郑州 450046
基金项目:国家自然科学基金面上项目(81573881);河南省高等学校重点科研项目(15A360030);国家级创新学习项目(S201810471013);河南中医药大学创新学习项目(CXXM[2017]0252)
摘    要:目的:观察二陈汤加味对慢性阻塞性肺病(COPD)大鼠细支气管中白细胞介素-19(IL-19),及其受体IL-20R_1,IL-20R_2表达的影响,探索二陈汤加味对COPD抗炎的机制。方法:用香烟烟雾联合脂多糖(LPS)制备COPD大鼠模型,将实验大鼠随机分为6组:正常组,模型组,二陈汤加味高、中、低剂量组,急支糖浆组。正常组与模型组灌生理盐水4 m L·d~(-1),二陈汤加味高、中、低剂量组(20,10,5 g·kg~(-1)·d~(-1)),急支糖浆组(12 g·kg~(-1)·d~(-1)),各组均连续灌胃14 d,2次/d。观察大鼠一般情况;评价大鼠肺功能;酶联免疫吸附测定(ELISA)检测大鼠血清中IL-10,IL-19和IL-20的含量;光镜观察大鼠细支气管组织病理变化;免疫组化检测大鼠细支气管组织中IL-20R_1和IL-20R_2的表达情况。结果:与正常组比较,模型组的最大呼吸流量(PEF),1 s用力呼吸容积(FEV_1),用力肺活量(FVC),FEV_1/FVC的值均显著降低(P0.05),血清中IL-19,IL-20的含量明显升高(P0.05),IL-10含量明显降低(P0.05),细支气管组织中IL-20R_1,IL-20R_2的表达明显升高(P0.05)。与模型组比较,急支糖浆组、二陈汤加味高、中、低剂量组的PEF,FEV_1,FVC,FEV_1/FVC均明显升高(P0.05);血清中IL-19,IL-20的含量明显降低(P0.05),IL-10含量明显升高(P0.05);细支气管组织中IL-20R_1,IL-20R_2的表达明显降低(P0.05)。结论:二陈汤加味可以改善COPD大鼠的肺功能,保护细支气管的组织结构,其机制可能与二陈汤加味抑制大鼠细支气管中IL-19,IL-20及其受体IL-20R_1,IL-20R_2的表达有关。

关 键 词:慢性阻塞性肺疾病  二陈汤  白细胞介素-19(IL-19)  IL-20  受体
收稿时间:2019/6/6 0:00:00

Effect of Modified Erchentang on Expression of IL-19,IL-20R1,IL-20R2 in Bronchioles of Rats with Chronic Obstructive Pulmonary Disease
XU Li-li,SHANG Li-zhi,WANG Bo-yu,YANG Fan,DU Yi-hang,ZHANG Di,HUANG Ping-ping,FENG Xue,ZHANG Dong-jie,FENG Yi-Hui and XIE Wen-ying.Effect of Modified Erchentang on Expression of IL-19,IL-20R1,IL-20R2 in Bronchioles of Rats with Chronic Obstructive Pulmonary Disease[J].China Journal of Experimental Traditional Medical Formulae,2019,25(23):41-47.
Authors:XU Li-li  SHANG Li-zhi  WANG Bo-yu  YANG Fan  DU Yi-hang  ZHANG Di  HUANG Ping-ping  FENG Xue  ZHANG Dong-jie  FENG Yi-Hui and XIE Wen-ying
Institution:Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China,Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China,Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China,Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China,Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China,Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China,Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China,Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China,Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China,Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China and Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China
Abstract:Objective: To observe the effect of modified Erchentang on the expression of interleukin-19 (IL-19), interleukin-20 (IL-20)and their receptor IL-20R1, IL-20R2 in bronchioles of rats with chronic obstructive pulmonary disease (COPD), and to explore the molecular mechanism of modified Erchentang on anti-inflammatory of COPD. Method: The model of rat with COPD was established by cigarette smoke combined with lipopolysaccharide (LPS). The experimental rats were randomly divided into 6 groups:normal group, model group, modified Erchentang high, medium and low dose group, and Jizhitangjiang group. Normal group and model group fed with normal saline 4 mL · d-1, modified Erchentang high, middle, low dosage group(20,10,5 g · kg-1 · d-1).The dosage of Jizhitangjiang group was 12 g · kg-1 · d-1, all groups were given intragastric administration for 14 days, twice a day. To observe the general situation of rats.To evaluate the pulmonary function of rats. To detect the contents of IL-10, IL-19 and IL-20 in serum by enzyme-linked immunosorbent assay (ELISA).To observe the pathological changes of bronchiole tissue by light microscopy.To detect the expression of IL-20R1 and IL-20R2 in bronchiole tissue by immunohistochemistry. Result: Compared with normal group, peak expiratory flow(PEF), forced expiratory volume in one second(FEV1), forced vital capacity (FVC), and FEV1/FVC in model group were significantly increased (P<0.05), the content of IL-19, IL-20 in serum significantly increased(P<0.05), the content of IL-10 in serum was significantly decreased (P<0.05), the expression of IL-20R1 and in bronchioles tissue significantly increased (P<0.05). Compared with model group, the PEF, FEV1, FVC, FEV1/FVC of Jizhitangjiang group, modified Erchentang high, medium and low dosage group were significantly increased(P<0.05).The content of IL-19, IL-20 in serum significantly decreased(P<0.05), the content of IL-10 in serum was significantly increased (P<0.05), the expression of IL-20R1 and IL-20R2 in bronchioles tissue was significantly decreased (P<0.05). Conclusion: Modified Erchentang can improve the lung function and protect the tissue structure of bronchioles in COPD rats, which may be related to the inhibition of the expression of IL-19, IL-20 and their receptor IL-20R1, IL-20R2 in bronchioles of rats with modified Erchentang.
Keywords:chronic obstructive pulmonary disease(COPD)  Erchentang  interleukin-19(IL-19)  IL-20  receptor
本文献已被 CNKI 等数据库收录!
点击此处可从《中国实验方剂学杂志》浏览原始摘要信息
点击此处可从《中国实验方剂学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号